Mother vs Baby: Addressing the Condundrum of Managing Preeclampsia

Thursday, March 16, 2017
4:00 PM to 6:00 PM (EDT)
CURE Innovation Commons, 93 Shennecossett Road, Groton

Event Details:
Bioscience ClubhouseCT invites technology experts, entrepreneurs, investors, and ecosystem supporters to hear from Wendy Davis about the technology growth of her company, GestVision.  Due to a complication of the pregnancy known as Preeclampsia, every 10 minutes a mom-to-be almost dies in the US, and we deliver three times as many premature babies than in any other high-income country.  Conservatively the condition is responsible for 76,000 maternal and 500,000 infant deaths each year worldwide. Despite this, there are no in vitro diagnostic products specific for preeclampsia in the US.  Preeclampsia remains elusive, typically identified by the nonspecific symptoms of high blood pressure and urine protein. At GestVision we believe better outcomes for both mother and baby are possible with a specific diagnosis. Founded to address unmet medical needs in women’s health, GestVision is initially focused on developing a rapid diagnostic test for preeclampsia based on novel proteomic insights licensed from Yale.  

Wendy is the Founder and CEO of GestVision, Inc. a CT biotechnology startup company committed to securing safer pregnancies.  The Company’s initial focus is the commercialization of a novel diagnostic for preeclampsia, a potentially life-threatening complication of pregnancy. Wendy has 20+ years’ experience in biotechnology cultivating early stage inventions through to commercialization.  Previously, she was instrumental in the successful exit of HistoRx, acquired by Novartis. Wendy is a graduate of Yale’s MBA: Leadership in Healthcare program.  

Sponsored by Angel Investor Forum, CT Next, Medtronic, and Elm Street Ventures.